BETA: Please send your feedback!
Celgene
CELG:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
About

Biotechnology
Founded 1986
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
website
Headquarters
Executives
Name | Title | Gender |
Isaac Blech | Founder | Male |
Mark J. Alles | Chief Executive Officer & Director | Male |
Sol J. Barer, PhD | Founder | Male |
Robert J. Hugin, MBA | Executive Chairman | Male |
Richard Cecil Eversfield Morgan | Founder | Male |
Peter N. Kellogg, MBA | Chief Financial Officer & Executive Vice President | Male |
Patrick E. Flanigan, III | Vice President-Investor Relations | Male |
Joseph S. Camardo, MD | Senior Vice President-Global Medical Affairs | Male |
Scott Andrew Smith | President & Chief Operating Officer | Male |
David Stirling | Founder | Male |
Gerald F. Masoudi | Secretary, Executive VP & General Counsel | Male |
Rupert Vessey, PhD | President-Research & Early Development | Male |
Mindful Investing Summary
Celgene - Competitors and Related Companies
How Celgene stacks up to its peers in the Biotechnology industry or with competing business segments.
Celgene
CELG:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2021
—
- 3
- 1
- 3
- —
- 3
- 5
- 5
- 1
- 5
- —
- —
- 4
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Amgen
AMGN:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 5
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Gilead Sciences
GILD:NAS
Biotechnology
—
MEGA cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership
Alexion Pharmaceuticals
ALXN:NAS
Biotechnology
—
LARGE cap
(—)
—
since start of 2021
—
- 5
- 5
- 4
- 5
- —
- 4
- 5
- 4
- —
- —
- —
- 4
-
Carbon Footprint
-
Pollution Prevention
-
Water Conservation
-
Data & Privacy Protection
-
Consumer Health, Wellness & Safety
-
Employee Ownership, Satisfaction, Benefits & Pay
-
Workplace Health and Safety
-
Integrity of Corporate Governance
-
Ethical Practices
-
Usage of Conflict Materials
-
Forced Labor
-
Diversity of Corporate Leadership